SavedAdd your journal

Journals / Turkish Journal of Chemistry / 2005 / Cilt: 29 - Sayı: 6

A new approach towards $(pm)$-4-ipomeanol and its 2-furyl regioisomer

Jürgen KRAUSS
Franz BRACHER
Doris UNTERREITMEIER
Pages
635–639
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The resulting compounds were tested in an agar diffusion assay against several bacteria and fungi, but did not show significant activity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The cytotoxic furan derivative $(pm)$-4-ipomeanol (1) and its regioisomer (8) were prepared in a new and efficient way starting from commercially available furan derivatives.
📊
Key Findings & Data:In both cases the key step was a regioselective solvolysis of the terminal double bond with trifluoroacetic anhydride and boron trifluoride.
💡
Conclusion & Impact:The resulting compounds were tested in an agar diffusion assay against several bacteria and fungi, but did not show significant activity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The cytotoxic furan derivative $(pm)$-4-ipomeanol (1) and its regioisomer (8) were prepared in a new and efficient way starting from commercially available furan derivatives. In both cases the key step was a regioselective solvolysis of the terminal double bond with trifluoroacetic anhydride and boron trifluoride. The resulting compounds were tested in an agar diffusion assay against several bacteria and fungi, but did not show significant activity.

🔖

Cite This Article

KRAUSS, J., BRACHER, F., UNTERREITMEIER, D. (2022). A new approach towards $(pm)$-4-ipomeanol and its 2-furyl regioisomer. Turkish Journal of Chemistry, Cilt: 29 - Sayı: 6, 635–639. https://ajindex.com/articles/602224

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. M.R. Boyd, and B.J. Wilson, J. Agric. Food. Chem. 20, 428-430 (1972). 2.L.T. Burka, L. Kuhnert, B.J. Wilson, and T.M. Harris, J. Am. Chem. Soc. 99, 2302-2305 (1977). 3.M.C. Christian, R.E. Wittes, B. Leyland-Jones, T.L. Me Lemore, A.C. Smith, C.K. Grieshaber, B.A. Chabner,and M.R. Boyd, J. Nat. Cancer Inst. 81, 1133-1143 (1989). 4.S.M. Smiley-Jewell, and C.G. Plopper, Toxicol. Appl. Pharm. 192, 69-77 (2003). 5.S. Lakhanpal, R.C. Donehower, and E.K. Rowinsky, Invest. New Drug. 19, 69 - 76 (2001). 6.R. Boyd, B.J. Wilson, and T.M. Harris, Nat. New Biol. 236, 158-159 (1972). 7.J. Krauss, D. Unterreitmeier, and D. Antlsperger, Arch. Pharm. Pharm. Med. Chem. 336, 381-384(2003). 8.J. Krauss, and D. Unterreitmeier, Arch. Pharm. Pharm. Med. Chem. 335, 94-98 (2002). 9.D.B,. Dess, and J.C. Martin, J. Org. Chem. 48, 4155-4156 (1983). 10.RE. Peterson, J. Am. Chem. Soc. 82, 5834-5837 (1960). 11.W.H. Liu, and H.J. Wu, J. Chin. Chem. Soc. 35, 241-246 (1988). 12.K. Fischer, and S. Huenig, J. Org. Chem. 52, 564-569 (1987). 13.B.R. Baer, A.E. Rettie, and K.R. Henne, Chem. Res. Toxicol. 18, 855-864 (2005).